Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation-Reference-Cited by-同舟云学术

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

Published:2014-06-05 Issue:23 Volume:123 Page:3664-3671
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Armand Philippe¹,Kim Haesook T.²,Logan Brent R.³⁴,Wang Zhiwei³,Alyea Edwin P.¹,Kalaycio Matt E.⁵,Maziarz Richard T.⁶,Antin Joseph H.¹,Soiffer Robert J.¹,Weisdorf Daniel J.⁷,Rizzo J. Douglas³,Horowitz Mary M.³,Saber Wael³

Affiliation:

1. Department of Medical Oncology and

2. Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston MA;

3. Center for International Blood and Marrow Transplant Research, Department of Medicine and

4. Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI;

5. Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH;

6. Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, OR; and

7. Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

Abstract

Key Points The DRI successfully stratified patients in a very large allogeneic transplantation registry cohort. The DRI was refined by using this cohort to build a more inclusive and conditioning intensity–independent index.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/23/3664/1378059/3664.pdf

Reference17 articles.

1. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival.;Weisdorf;Biol Blood Marrow Transplant,2008

2. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.;Sorror;Blood,2005

3. A disease risk index for patients undergoing allogeneic stem cell transplantation.;Armand;Blood,2012

4. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.;Slack;Biol Blood Marrow Transplant,2013

5. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.;Thanarajasingam;Biol Blood Marrow Transplant,2013

Cited by 706 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of CD34 positive cell dose in donor graft on the outcomes after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide – A retrospective single-center study with a Japanese cohort;Blood Cells, Molecules, and Diseases;2024-03

2. Longitudinal clinical data improve survival prediction after hematopoietic cell transplantation using machine learning;Blood Advances;2024-02-13

3. Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms;Blood Advances;2024-02-13

4. Hematopoietic cell transplantation (HCT) in MDS patients of older age;Leukemia & Lymphoma;2024-02-05

5. Human herpesvirus type 6 reactivation after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide and antithymocyte globulin: risk factors and clinical impact;Clinical Hematology International;2024-02-02